Abstract

Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined. Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment. Notably, we detected an ALK 1196M resistance mutation in a CRC patient who received multiple lines of chemotherapy and ALKi treatment. Importantly, we found that Brigatinib and Lorlatinib demonstrated some efficacy in managing this patient, although the observed effectiveness was not as pronounced as in non-small cell lung cancer cases. Furthermore, based on our preliminary analyses, we surmise that ALK-positive CRC patients are likely to exhibit inner resistance to Cetuximab. Taken together, our findings have important implications for the treatment of ALK-positive CRC patients.

Details

Title
Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis
Author
Li, Zi-Jing 1 ; Pat Fong, William 1 ; Zhang, Dong-Sheng 1 ; Luo, Hui-Yan 1 ; Chen, Dong-Liang 1 ; Cai, Yan-Yu 1 ; Chen, Zhi-Gang 1 ; Duan, Jian-Li 1 ; Huang, Zi-Yao 1 ; Lu, Yu-Ting 1 ; Huang, Xiao-Xia 1 ; Li, Yu-Hong 1 ; Wang, De-Shen 1   VIAFID ORCID Logo 

 Sun Yat-sen University Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, P. R. China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191) 
Pages
100
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3054313335
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.